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Exosomal MicroRNA for Detection of Cardiac Sarcoidosis
To the Editor:
Sarcoidosis is a multisystem, granulomatous disease of unknown cause that most commonly affects adults 25-50 years of age, causing significant morbidity and mortality. Studies indicate that sarcoidosis-related mortality is on the rise, perhaps relating to improved disease detection (1) . Cardiac sarcoidosis (CS) is the second leading cause of sarcoidosis-related death, and young adults are particularly at risk (2) . A contributing factor is failure to detect CS during routine clinical screening, including patient history, physical examination, and electrocardiography (1) . As a result, many cases are detected for the first time after a cardiovascular complication, ranging from frequent premature ventricular contractions and atrial arrhythmias to sudden cardiac death (1) . Whereas high-resolution cardiac imaging techniques, such as cardiac magnetic resonance or fludeoxyglucose F 18-positron emission tomography/computed tomography ([ 18 F]FDG-PET/CT), greatly improve CS detection (1) , these modalities are expensive and present certain patient risks (e.g., radiation exposure with [ 18 F]FDG-PET/CT [3] ), making them impractical for routine screening for CS. To our knowledge, no circulating biomarker has been shown to reliably detect CS.
Noncoding RNAs are readily detected in human blood and are reported to serve as biomarkers of diseases including acute myocardial damage (4) . A fraction of the microRNAs (miRNAs) in blood are encapsulated within lipid bilayer vesicles, referred to as exosomes, where they are shielded from enzymatic degradation (5) . Exosomes originate from multivesicle bodies within cells containing proteins, nucleic acids, and lipids, and as such, exosomal molecular content reflects its cellular origin (6) . Thus, we hypothesized that exosome-derived miRNA could serve as an informative source of biomarkers for cardiac sarcoidosis.
With institutional review board approval, we conducted a retrospective study of 21 subjects with histologically proven sarcoidosis who had clinical and radiographic evidence of CS, based on established criteria (7, 8) , compared with 21 subjects with sarcoidosis with no evidence of CS (non-CS), and 11 healthy human volunteers. We randomly divided the plasma samples obtained into two groups: discovery (10 CS, 10 non-CS, and 5 control) and validation (11 CS, 11 non-CS, and 6 control) cohorts. The demographic and clinical characteristics are presented in Table 1 , with no significant differences found between the groups in any of the demographic characteristics. The plasma samples were collected within the scope of the National Institutes Ipswich, MA) and then run on NextSeq 500 high-output kits (Illumina, San Diego, CA) with single-end 50-nucleotide read length. Data processing and mapping were performed as described previously (9) , with subsequent miRNA expression internally normalized to miR-16 levels because of its low concentration variation among samples used in the study (three independent real-time quantitative reverse transcription-polymerase chain reaction [qRT-PCR] results from validation samples are shown in Figure 1A ). Statistical comparisons of differentially expressed miRNAs (identified when comparing the CS and non-CS groups) were corrected for multiple hypothesis testing, based on the Benjamini-Hochberg procedure to reduce false discovery (10) .
The concentrations of 13 miRNAs were specifically different in exosomes, and not in plasma or exosome-depleted plasma, using a twofold concentration change threshold when comparing CS with non-CS (P , 0.05). These miRNAs were as follows: miR-7-1-3p, miR-32-3p, miR-211-5p, miR-409-5p, miR-517a-3p, miR-548u-3p, miR-660-3p, miR-942-3p, miR-1262-5p, miR-3179-1-3p, miR-3940-3p, miR-6855-5p, and miR-7854-5p. Among these, we selected several of the most affected miRNAs (miR-7-1-3p, miR-32-3p, miR-211-5p, and miR-548u-3p) for evaluation by qRT-PCR (normalized to miR-16) in the validation cohort. Notably, miR-7-1-3p and miR-211-5p are reported biomarkers of ischemic heart disease (11) (12) (13) . The concentrations of these miRNAs were significantly different in all patients with sarcoidosis, taken collectively, relative to control subjects. Two (miR-32-3p and miR-211-5p) were found to have higher concentrations in the non-CS group compared with the CS group, and miR-7-1-3p was shown by qRT-PCR to be significantly elevated in patients with CS ( Figure 1B) . The concentration of miR-548u-3p was not significantly different between the CS and non-CS groups within the validation cohort.
Exosomal contents offer a rich source of potential biomarkers and may reflect the underlying molecular mechanisms of disease (5) . miR-7-1-3p and miR-211-5p have been shown to be markers of, and in the case of miR-7-1-3p, incriminated in the pathogenesis of ischemic cardiac disease (11) (12) (13) . However, the role of miR-7 in the pathogenesis of CS, if any, remains to be determined.
Despite the small sample size, statistically significant concentration differences for specific exosomal miRNAs were apparent. Given the known limitations of NGS technologies (14) , it was recommended to validate the results using techniques such as qRT-PCR. Limited by the small quantities of RNA obtained from exosomes, we were able to validate only a few selected miRNAs. Although the exosome isolation kit has been claimed to be highly selective (15) , there is a significant amount of protein copurified with exosomes. It is possible that some of the miRNA/protein complexes were coprecipitated in the exosomal fraction. Nevertheless, our NGS data showed that the concentration changes for each of the 13 differentially expressed miRNAs were observed only in the exosomal fraction of the plasma and not in the exosome-depleted plasma samples. Even though ultracentrifugation offers a more pure exosomal isolation, it is low throughput, time-consuming, and prohibitory for use in most clinical applications with limited sample size. Given the risks and low sensitivity of myocardial biopsy, the diagnosis of CS is typically established on the basis of clinical criteria. In this regard, advanced imaging modalities, including magnetic resonance imaging and [ 18 F]FDG-PET/CT scan, are considered to be highly sensitive for the detection of CS (1) and can differentiate active inflammation from more chronic disease manifestations (e.g., fibrosis) (16) . We suspect that the performance of an exosomal miRNA-based CS biomarker would be even better if we restricted the analysis to samples from those having evidence of active myocardial inflammation.
Our study suggests that specific exosomal miRNAs could serve as biomarkers of myocardial involvement in patients with sarcoidosis. Further investigation is needed to determine whether exosomal miRNA can reflect changes in cardiac activity (e.g., in response to immune suppression) or whether miRNA markers from exosomes can detect and differentiate other sarcoidosis phenotypes (e.g., neurosarcoidosis). n
